북미의 마이크로바이옴 치료제 시장 예측(-2030년) : 지역별 분석 - 유형별, 용도별, 최종사용자별

The North America microbiome therapeutics market was valued at US$ 161.64 million in 2022 and is expected to reach US$ 342.99 million by 2030; it is estimated to record a CAGR of 9.9% from 2022 to 2030.

Inflow of Funds to Ameliorate Microbiome Discovery Pipeline Drives North America Microbiome Therapeutics Market

Research has shown that imbalances or disruptions in the microbiome can contribute to various conditions, such as inflammatory bowel disease and obesity, as well as mental health disorders. The recognition of the microbiome's role in overall health has generated significant interest in developing therapeutics to target and modulate the microbiome. Additionally, advancements in technology and research tools have made it easier to study and manipulate the microbiome. Next-generation sequencing and metagenomic analysis have allowed for a deeper understanding of microbial communities and their functions. The increased knowledge has opened up new possibilities for developing targeted therapies. Regulatory agencies such as the US Food and Drug Administration (FDA) have also shown a willingness to support the development of microbiome therapeutics. The FDA has established guidelines for FMT and has expressed interest in advancing the field through regulatory pathways that ensure safety and efficacy. All these factors combined have created a favorable investment climate for companies working in the field of microbiome therapeutics.

As strong clinical evidence becomes available, investors are beginning to take notice of microbiome modulator firms. The heightened funding provides companies with necessary resources to overcome the challenges associated with the high cost of development and production, ultimately driving the field forward.

North America Microbiome Therapeutics Market Overview

The increasing understanding of the importance of the human microbiome in maintaining health and preventing diseases has led researchers in the US to explore microbiome-based interventions as a promising approach to treating various conditions. Additionally, the dominance of this country in the North America microbiome therapeutics market is mainly attributed to its well-developed research infrastructure that favors the development of innovative treatments Further, the rising prevalence of chronic diseases such as obesity and inflammatory bowel disease has created a demand for innovative treatments, spurring the development of microbiome therapeutics. Technological advancements in gene sequencing and bioinformatics enable the study and alteration of the microbiome, facilitating the development of personalized microbiome-based interventions. The trend toward personalized medicine aligns well with tailormade microbiome therapeutics. Collaborations between academia, industry, and government organizations are also fueling research and development efforts, accelerating the translation of scientific discoveries into commercial products. Regulatory support and investment in the field further contribute to market growth, as regulatory bodies recognize the potential of microbiome therapeutics and provide guidance for their development and approval.

North America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Million)

North America Microbiome Therapeutics Market Segmentation

The North America microbiome therapeutics market is segmented based on type, application, end user, and country.

Based on type, the North America microbiome therapeutics market is bifurcated into therapeutics and procedure. The procedure segment held a larger share in 2022. The therapeutics segment is further subsegmented into fecal microbiota transplantation (FMT), prebiotics & probiotics, and others.

By application, the North America microbiome therapeutics market is segmented into metabolic disorder and obesity, C. difficile infection, inflammatory bowel disease, and others. The C. difficile infection segment held the largest share in 2022.

By end user, the North America microbiome therapeutics market is hospitals and clinics, ambulatory surgical centers, homecare, and others. The hospitals and clinics segment held the largest share in 2022.

Based on country, the North America microbiome therapeutics market is segmented into the US, Canada, and Mexico. The US dominated the North America microbiome therapeutics market in 2022.

AOBiome Therapeutics Inc, Ferring Holdings SA, Finch Therapeutics Group Inc, Pendulum Therapeutics Inc, and Seres Therapeutics Inc are some of the leading companies operating in the North America microbiome therapeutics market.

Table Of Contents

1. Introduction

• 1.1 The Insight Partners Research Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Key Insights

3. Research Methodology

• 3.1 Coverage
• 3.2 Secondary Research
• 3.3 Primary Research

4. North America Microbiome Therapeutics Market Landscape

• 4.1 Overview
• 4.2 North America PEST Analysis

5. North America Microbiome Therapeutics Market - Key Industry Dynamics

• 5.1 North America Microbiome Therapeutics Market - Key Industry Dynamics
• 5.2 Key Market Drivers
  • 5.2.1 Potential of Gut Microbiota in Maintaining Human Health
  • 5.2.2 Inflow of Funds to Ameliorate Microbiome Discovery Pipeline
• 5.3 Key Market Restraints
  • 5.3.1 High Cost of Development and Production
• 5.4 Key Market Opportunities
  • 5.4.1 Increasing R&D to Gain Better Understanding of Human Microbiome
• 5.5 Key Future Trends
  • 5.5.1 Technological Advancement in Human Microbiome Therapeutics
• 5.6 Impact of Drivers and Restraints:

6. Microbiome Therapeutics Market - North America Market Analysis

7. North America Microbiome Therapeutics Market Analysis - Type

• 7.1 Therapeutics
  • 7.1.1 Overview
  • 7.1.2 Therapeutics Market, Revenue and Forecast to 2030 (US$ Thousand)
• 7.2 Procedure
  • 7.2.1 Overview
  • 7.2.2 Procedure Market, Revenue and Forecast to 2030 (US$ Thousand)

8. North America Microbiome Therapeutics Market Analysis - Application

• 8.1 Metabolic Disorder and Obesity
  • 8.1.1 Overview
  • 8.1.2 Metabolic Disorder and Obesity Market, Revenue and Forecast to 2030 (US$ Thousand)
• 8.2 C. Difficile Infection (CDI)
  • 8.2.1 Overview
  • 8.2.2 C. Difficile Infection (CDI) Market, Revenue and Forecast to 2030 (US$ Thousand)
• 8.3 Inflammatory Bowel Disease
  • 8.3.1 Overview
  • 8.3.2 Inflammatory Bowel Disease Market, Revenue and Forecast to 2030 (US$ Thousand)
• 8.4 Others
  • 8.4.1 Overview
  • 8.4.2 Others Market, Revenue and Forecast to 2030 (US$ Thousand)

9. North America Microbiome Therapeutics Market Analysis - End User

• 9.1 Hospitals and Clinics
  • 9.1.1 Overview
  • 9.1.2 Hospitals and Clinics Market, Revenue and Forecast to 2030 (US$ Thousand)
• 9.2 Ambulatory Surgical Centers
  • 9.2.1 Overview
  • 9.2.2 Ambulatory Surgical Centers Market, Revenue and Forecast to 2030 (US$ Thousand)
• 9.3 Homecare
  • 9.3.1 Overview
  • 9.3.2 Homecare Market, Revenue and Forecast to 2030 (US$ Thousand)
• 9.4 Others
  • 9.4.1 Overview
  • 9.4.2 Others Market, Revenue and Forecast to 2030 (US$ Thousand)

10. North America Microbiome Therapeutics Market - Country Analysis

• 10.1 North America Microbiome Therapeutics Market Revenue and Forecasts and Analysis - By Country
  • 10.1.1 North America Microbiome Therapeutics Market Revenue and Forecasts and Analysis - By Country
  • 10.1.2 US
    • 10.1.2.1 US: North America Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
    • 10.1.2.2 US: North America Microbiome Therapeutics Market Breakdown by Type
      • 10.1.2.2.1 US North America Microbiome Therapeutics Market Breakdown by Therapeutics
    • 10.1.2.3 US: North America Microbiome Therapeutics Market Breakdown by Application
    • 10.1.2.4 US: North America Microbiome Therapeutics Market Breakdown by End User
  • 10.1.3 Canada
    • 10.1.3.1 Canada: North America Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
    • 10.1.3.2 Canada: North America Microbiome Therapeutics Market Breakdown by Type
      • 10.1.3.2.1 Canada North America Microbiome Therapeutics Market Breakdown by Therapeutics
    • 10.1.3.3 Canada: North America Microbiome Therapeutics Market Breakdown by Application
    • 10.1.3.4 Canada: North America Microbiome Therapeutics Market Breakdown by End User
  • 10.1.4 Mexico
    • 10.1.4.1 Mexico: North America Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
    • 10.1.4.2 Mexico: North America Microbiome Therapeutics Market Breakdown by Type
      • 10.1.4.2.1 Mexico: North America Microbiome Therapeutics Market Breakdown by Therapeutics
    • 10.1.4.3 Mexico: North America Microbiome Therapeutics Market Breakdown by Application
    • 10.1.4.4 Mexico: North America Microbiome Therapeutics Market Breakdown by End User

11. Industry Landscape

• 11.1 Overview
• 11.2 Growth Strategies in North America Microbiome Therapeutics Market

12. Company Profiles

• 12.1 Ferring Holdings SA
  • 12.1.1 Key Facts
  • 12.1.2 Business Description
  • 12.1.3 Products and Services
  • 12.1.4 Financial Overview
  • 12.1.5 SWOT Analysis
  • 12.1.6 Key Developments
• 12.2 Vedanta Biosciences Inc
  • 12.2.1 Key Facts
  • 12.2.2 Business Description
  • 12.2.3 Products and Services
  • 12.2.4 Financial Overview
  • 12.2.5 SWOT Analysis
  • 12.2.6 Key Developments
• 12.3 Finch Therapeutics Group Inc
  • 12.3.1 Key Facts
  • 12.3.2 Business Description
  • 12.3.3 Products and Services
  • 12.3.4 Financial Overview
  • 12.3.5 SWOT Analysis
  • 12.3.6 Key Developments
• 12.4 Pendulum Therapeutics Inc
  • 12.4.1 Key Facts
  • 12.4.2 Business Description
  • 12.4.3 Products and Services
  • 12.4.4 Financial Overview
  • 12.4.5 SWOT Analysis
  • 12.4.6 Key Developments
• 12.5 Seres Therapeutics Inc
  • 12.5.1 Key Facts
  • 12.5.2 Business Description
  • 12.5.3 Products and Services
  • 12.5.4 Financial Overview
  • 12.5.5 SWOT Analysis
  • 12.5.6 Key Developments
• 12.6 AOBiome Therapeutics Inc
  • 12.6.1 Key Facts
  • 12.6.2 Business Description
  • 12.6.3 Products and Services
  • 12.6.4 Financial Overview
  • 12.6.5 SWOT Analysis
  • 12.6.6 Key Developments

13. Appendix

• 13.1 About The Insight Partners
• 13.2 Glossary of Terms